Replimune Group (NASDAQ:REPL) Upgraded to “Overweight” by JPMorgan Chase & Co.
Replimune Group (NASDAQ:REPL) was upgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued to investors on Friday, Marketbeat reports. The firm presently has a $26.00 target price on the stock, down from their prior target price of $27.00. JPMorgan Chase & Co.‘s target price suggests a potential upside of 98.17% from the company’s previous close.
REPL has been the subject of a number of other reports. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Wedbush cut their target price on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 24th. Finally, HC Wainwright set a $73.00 target price on shares of Uniqure and gave the company a “buy” rating in a report on Monday, July 8th. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $24.67.
REPL stock opened at $13.12 on Friday. The firm has a fifty day simple moving average of $13.53. Replimune Group has a fifty-two week low of $8.88 and a fifty-two week high of $23.55. The company has a quick ratio of 14.26, a current ratio of 14.26 and a debt-to-equity ratio of 0.05.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Story: Conference Calls and Individual Investors
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.